## **ERITREA**

#### **BURDEN OF CANCER**



Premature deaths from NCDs (2016) 7,416


Cancer as % of NCD premature deaths (2016)

25.1%



Most common cancer cases (2018)





# PAFS (population attributable fractions)

Tobacco (2017)<sup>a</sup> Alcohol (2016)<sup>a</sup>

<sup>b</sup> PAF, cancer cases

Oesophagus

Ovary

Infections (2012)<sup>b</sup> Obe

<sup>c</sup> PAF, melanoma cases

Obesity (2012)<sup>b</sup> UV (2012)<sup>c</sup>


Occupational risk (2017)<sup>a</sup>

### **TRENDS**


#### Estimated past and future trends in total cases per year (breast and lung)

<sup>a</sup> PAF, cancer deaths

5.2%




#### Probability of premature death from cancer per year




#### **INVESTMENT CASE (2019)**









Other childhood cancer

## **ERITREA**

vailability of population-based cancer	2019	No information	WORKFORCE			
egistry (PBCR)**			° per 10,000 cancer patients  Available staff in Ministry of Health who			
uality of mortality registration***	2007-2016	No coverage	dedicates significant proportion of their time to cancer	2019	ye	
of external beam radiotherapy	2019	0.0	# of radiation oncologist <sup>a</sup>	2019	n/s	
photon,electron) <sup>a</sup>			# of medical physicist <sup>a</sup>	2019	3.	
of mammographs <sup>a</sup>	2020	12.7	# of surgeons <sup>a</sup>	n/a	n/	
of CT scanners <sup>a</sup>	2020	6.4	# of radiologist <sup>a</sup>	2019	n/	
of MRI scanners <sup>a</sup>	2020	3.2	# of nuclear medicine physician <sup>a</sup>	2019	0.	
of PET or PET/CT scanners <sup>a</sup>	2020	0.0	# of medical & pathology lab scientists <sup>a</sup>	2004	54.	
ORMULATING RESPONSE						
ntegrated NCD plan	2019	operational	# Public cancer centres per 10,000 cancer patients	2019	n/a	
ICCP (including cancer types)	2019	n/a	Early detection programme/ guidelines for 4 cancers (breast, cervix, colon, childhood)	2019	0 cancer(s	
IPOWER measures fully implemented and chieved	2018	1	Pathology services	2019	generally availabl	
ancer management guidelines	2019	no	Bone marrow transplantation capacity	2019	generally no availabl	
alliative care included in their operational, ntegrated NCD plan	2019	yes	Palliative care availability: community/home-based care	2019	generally no availabl	
of treatment services (surgery, adiotherapy, chemotherapy)	2019	0	Availability of opioids* for pain management	2015-2017		
reast cancer screening program	2019	no	*Defined daily doses for statistical purposes (S-DDD) per i	niliion inhabitants	per day	
reast cancer screening program: Starting ge, target population	2019	n/a				
GLOBAL INITIATIVES						
limination of Cervical Cancer			Global Initiative for Childhood Cancer			
PV vaccination programme coverage	2018	n/a	Annual cancer cases (0-14 years old)	2020	19	
ervical cancer screening	2019	no	Early detection programme/guidelines	2019	n	
creening programme type	2019	n/a	Defined referral system	2019	n	
creening programme method	2019	n/a				
creening participation rates	2019	n/a	Annual cancer cases (0-14 years old)			
arly detection programme/guidelines	2019	no				
			25	■ Acute lymphoid leukaemia		
		yes	8 ■ Hodgkin lymphoma			
efined referral system	2019	,,,,				
efined referral system	2019	,	11	■ Burkit	t lymphoma	
efined referral system	2019	,	11 6		t lymphoma	
efined referral system	2019	,-	11	CNS, I		

<sup>\*\*</sup>The incidence estimates for this country have a high degree of uncertainty because they are not based on population based cancer registry
\*\*\*The mortality estimates for this country have a high degree of uncertainty because they are not based on any national NCD mortality data